Dr. Reddy's has no confirmed US launch yet among the blockbuster drugs on this tracker, holds FDA approval for 4 of them, and has 7 filed or in development. Those brands earned $100.1B in 2025. Of the 70 makers we follow, 3 are lined up to copy more of these drugs.
| Drug | Dr. Reddy's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| EntrestoGeneric · Novartis · US LOE 2025 | FDA-approved 13 Jan 2025 | 2 on sale · 13 approvedof 15 other makers listed | $7.7B |
| XareltoGeneric · Bayer / Johnson & Johnson · US LOE 2025 | FDA-approved 14 May 2025 | 1 on sale · 17 approvedof 19 other makers listed | ≈$5.3B |
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 31 Aug 2026 | 4 on sale · 5 approvedof 10 other makers listed | $2.7B |
| VenclextaGeneric · AbbVie · US LOE 2032 | FDA-approved 15 May 2026; settled Dec 2024 | 0 on sale · 0 approvedof 1 other maker listed | $2.8B |
| Drug | Dr. Reddy's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Prolia AVT03Biosimilar · Amgen · US LOE 2025 | Filed with the FDA; in litigation, sued Nov 2025. FDA turned it down in Dec 2025 over factory issues only; back under review after the FDA cleared the factory in Jul 2026 With Alvotech |
7 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva AVT03Biosimilar · Amgen · US LOE 2025 | Filed with the FDA; in litigation, sued Nov 2025. FDA turned it down in Dec 2025 over factory issues only; back under review after the FDA cleared the factory in Jul 2026 With Alvotech |
6 on sale · 4 approvedof 10 other makers listed | $2.1B |
| JakafiGeneric · Incyte · US LOE 2028 | Filed with the FDA; settled, terms confidential | 0 on sale · 0 approvedof 9 other makers listed | $3.1B |
| OzempicGeneric · Novo Nordisk · US LOE 2032 | Filed with the FDA; settled, terms confidential | 0 on sale · 1 approvedof 6 other makers listed | ≈$19.3B |
| Drug | Dr. Reddy's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Keytruda AVT32Biosimilar · Merck · US LOE 2028 | In clinical trials. US filing planned for 2028 With Alvotech |
0 on sale · 0 approvedof 9 other makers listed | $31.7B |
| Darzalex HLX15Biosimilar · Johnson & Johnson · US LOE 2029 | In clinical trials. First patient dosed May 2026 With Henlius |
0 on sale · 0 approvedof 1 other maker listed | $14.3B |
| Cosentyx BAT2306Biosimilar · Novartis · US LOE 2029 | In clinical trials. Phase 3 complete With Bio-Thera |
0 on sale · 0 approvedof 1 other maker listed | $6.7B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
Each row is a copy Dr. Reddy's sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Dr. Reddy's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Dr. Reddy's sales; several makers usually share a market once copies launch.
77 US generic applications pending; first to file on 27 (30 Sep 2026), across all products, not just the drugs tracked here.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: SEC company tickers; Dr. Reddy's 20-F, year to March 2026, Dr. Reddy's 6-K, quarter to September 2026.